Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314675 | 0.95 | TRPV1 (0.53) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL29954714 | 0.95 | CYP17A1 (0.57) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL2787414 | 0.95 | TRPV1 (0.53) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL12260944 | 0.92 | TRPV1 (0.50) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL9946011 | 0.88 | CYP17A1 (0.49) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL13055402 | 0.87 | CYP17A1 (0.59) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL12869625 | 0.85 | CYP17A1 (0.47) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL2055341 | 0.85 | CA1 (0.45) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL3789278 | 0.83 | CA12 (0.42) | TRPV1CYP17A1PSMB8NAMPTCA12 | |
| SCHEMBL23619661 | 0.82 | SMN1; SMN2 (0.62) | CYP17A1PSMB8NAMPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 934 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899492-B | Preparation method of modified polyurethane toughened epoxy resin | 湖北珍正峰新材料有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-119899492-A | Preparation method of modified polyurethane toughened epoxy resin | 湖北珍正峰新材料有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. | 2025-03-13 | — | — | US | claimed |
| EP-4430040-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | Janssen Biotech, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| CN-118201925-A | Macrocyclic compounds and methods of making the same | 詹森生物科技公司 | 2024-06-14 | — | — | CN | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| CN-115260052-B | 2-phenyl naphthalene derivative and preparation method and application thereof | 山东大学 | 2023-07-25 | — | — | CN | claimed |
| WO-2023084396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| CN-115869787-A | High-performance biological pollution-resistant nanofiltration membrane and preparation and application thereof | 华中科技大学 | 2023-03-31 | — | — | CN | claimed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | claimed |
| EP-3078658-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2016-10-12 | — | — | EP | claimed |
| US-9340575-B2 | Agonists and antagonists of the urotensinergic system | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2016-05-17 | — | — | US | claimed |
| EP-2729184-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | Institut National de la Recherche Scientifique (CA) | 2014-05-14 | — | — | EP | claimed |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-04-24 | — | — | US | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2012149644-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2012-11-08 | — | — | WO | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | PAICS, CD47, FURIN | TRPV1 4436/4885CYP17A1 479/4885PSMB8 2218/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | TRPV1 830/4885CYP17A1 4611/4885PSMB8 1740/4885 |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | UTS2R, SCTR, PLAUR | TRPV1 355/4885CYP17A1 3877/4885PSMB8 853/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | TRPV1 2974/4885CYP17A1 349/4885PSMB8 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.